MedTrace Logo

Allopurinol and Endothelial Function in Diabetic CAD Patients

NCT03385135 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2017-12-28

No results posted yet for this study

Summary

This is a randomized trial assessing the impact of allopurinol on endothelial function in optimally treated diabetic patients with coronary artery disease. After initial screening, subjects were randomized to receive either optimal medical therapy (OMT) + allopurinol or OMT alone for 8 weeks. The dose of allopurinol was 300 mg for 4 weeks and 600 mg for 4 weeks with a 4-weekly check on hematology and biochemistry

Conditions

Interventions

DRUG

Allopurinol

300 mg for 4 weeks then 600 mg for 4 weeks in the active group

Sponsors & Collaborators

  • University Tunis El Manar

    lead OTHER

Principal Investigators

  • Salem Kachboura, MD · Cardiology Department, Abderrahmen Mami Hospital, 2008, Ariana

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-31
Primary Completion
2018-03-31
Completion
2018-06-30

Countries

  • Tunisia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03385135 on ClinicalTrials.gov